Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational, Prospective Safety Study in Subjects With Type 2 Diabetes Mellitus Starting NovoMix® 30 (Biphasic Insulin Aspart) Treatment

NCT00696995 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00696995
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00696995 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational, Prospective Safety Study in Subjects With Type 2 Diabetes Mellitus Starting NovoMix® 30 (Biphasic Insulin Aspart) Treatment
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Completed
Start date
January 31, 2007
Completion date
September 30, 2008
Enrollment
509 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2